Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
NewsA phase 3 trial found that ultra-low-dose nivolumab (20 mg) paired with oral metronomic chemotherapy nearly doubled median overall survival compared to standard paclitaxel-carboplatin in recurrent/metastatic head and neck cancer — at a fraction of the cost. The results don't prove low-dose equals conventional dosing, but they spark a critical conversation about making immunotherapy accessible globally.
A randomized phase 3 trial (LBA6007) presented at the 2026 ASCO Annual Meeting showed that combining ultra-low-dose nivolumab (20 mg every 3 weeks) with triple oral metronomic chemotherapy (TMC-I) significantly outperformed paclitaxel-carboplatin in patients with platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The regimen costs approximately $230/month — a stark contrast to conventional immunotherapy pricing — and was developed with resource-limited settings in mind, particularly in low- and middle-income countries where fewer than 2% of eligible patients currently receive checkpoint inhibitors.
The trial's results were striking: better survival, better response rates, and fewer severe side effects than the control arm. But experts caution that this isn't a green light to routinely swap out standard-of-care pembrolizumab-based regimens — the comparator wasn't a contemporary immunotherapy regimen, and the contribution of the nivolumab dose alone cannot be isolated.
By the Numbers:
Why it matters: This trial challenges oncology to rethink dose optimization — not just for safety, but for equity. If meaningful outcomes can be achieved with less, more patients worldwide could actually receive life-extending treatment.
